Get started
Eli Lilly and CompanyEli Lilly and CompanyEli Lilly and Company

Eli Lilly and Company

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

LLY chart


Full chart

Key facts today

Eli Lilly's tirzepatide, sold as Mounjaro and Zepbound, is under FDA review due to a shortage lawsuit. Shares fell 0.5% as the FDA assesses compounding pharmacies producing cheaper alternatives.
Eli Lilly's obesity drug, Zepbound, has received FDA approval and is currently being compared to Amgen's experimental drug MariTide in the competitive obesity drug market.
Eli Lilly will invest £279 million in the UK to establish Lilly Gateway Labs, an innovation hub focused on early-stage life sciences firms targeting obesity treatments and enhancing health outcomes.
Analyze the impactAnalyze the impact

Upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪885.85 B‬USD
Dividend yield (indicated)
0.56%
Price to earnings Ratio (TTM)
116.43
Basic EPS (TTM)
8.03USD
Net income (FY)
‪5.24 B‬USD
Revenue (FY)
‪34.12 B‬USD
Shares float
‪851.72 M‬
Beta (1Y)
0.83

Employees


Employees (FY)
‪43 K‬
Revenue / Employee (1Y)
‪793.58 K‬USD
Net income / Employee (1Y)
‪121.87 K‬USD

About Eli Lilly and Company


Sector
Health Technology
CEO
David A. Ricks
Headquarters
Indianapolis
Website
lilly.com
Founded
1876
FIGI
BBG000BNBDC2
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Ideas



See all ideas 

News



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Analyze a symbol's price movements over past years with our seasonal tools, helping you spot repeating annual trends and better gauge potential market patterns.

Highest yielding bonds


US532457AM0
ELI LILLY 2025
LLY4099975
Eli Lilly and Company 4.65% 15-JUN-2044
LLY.GG
Eli Lilly and Company 6.77% 01-JAN-2036
LLY5871804
Eli Lilly and Company 5.2% 14-AUG-2064
LLY5750032
Eli Lilly and Company 5.1% 09-FEB-2064
LLY5547405
Eli Lilly and Company 4.95% 27-FEB-2063
LLY5750031
Eli Lilly and Company 5.0% 09-FEB-2054
LLY5871803
Eli Lilly and Company 5.05% 14-AUG-2054
LLY5547404
Eli Lilly and Company 4.875% 27-FEB-2053
US532457BU1
ELI LILLY 19/59
US532457BT4
ELI LILLY 19/49

Explore more bonds 

Sparks


Curated watchlists where LLY is featured.

See all sparks 

Frequently Asked Questions


The current price of LLY is 929.51 USD — it has increased by 2.35% in the past 24 hours. Watch Eli Lilly and Company stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange Eli Lilly and Company stocks are traded under the ticker LLY.
LLY stock has risen by 5.21% compared to the previous week, the month change is a 3.32% rise, over the last year Eli Lilly and Company has showed a 50.43% increase.
We've gathered analysts' opinions on Eli Lilly and Company future price: according to them, LLY price has a max estimate of 1,158.00 USD and a min estimate of 640.00 USD. Watch LLY chart and read a more detailed Eli Lilly and Company stock forecast: see what analysts think of Eli Lilly and Company and suggest that you do with its stocks.
LLY reached its all-time high on Aug 22, 2024 with the price of 972.53 USD, and its all-time low was 2.04 USD and was reached on Sep 21, 1977. View more price dynamics on LLY chart.
See other stocks reaching their highest and lowest prices.
LLY stock is 1.19% volatile and has beta coefficient of 0.83. Track Eli Lilly and Company stock price on the chart and check out the list of the most volatile stocks — is Eli Lilly and Company there?
Today Eli Lilly and Company has the market capitalization of ‪885.85 B‬, it has increased by 0.14% over the last week.
Yes, you can track Eli Lilly and Company financials in yearly and quarterly reports right on TradingView.
Eli Lilly and Company is going to release the next earnings report on Oct 30, 2024. Keep track of upcoming events with our Earnings Calendar.
LLY earnings for the last quarter are 3.92 USD per share, whereas the estimation was 2.74 USD resulting in a 42.93% surprise. The estimated earnings for the next quarter are 4.42 USD per share. See more details about Eli Lilly and Company earnings.
Eli Lilly and Company revenue for the last quarter amounts to ‪11.30 B‬ USD, despite the estimated figure of ‪9.98 B‬ USD. In the next quarter, revenue is expected to reach ‪12.16 B‬ USD.
LLY net income for the last quarter is ‪2.97 B‬ USD, while the quarter before that showed ‪2.24 B‬ USD of net income which accounts for 32.28% change. Track more Eli Lilly and Company financial stats to get the full picture.
Yes, LLY dividends are paid quarterly. The last dividend per share was 1.30 USD. As of today, Dividend Yield (TTM)% is 0.54%. Tracking Eli Lilly and Company dividends might help you take more informed decisions.
Eli Lilly and Company dividend yield was 0.78% in 2023, and payout ratio reached 77.91%. The year before the numbers were 1.07% and 56.79% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Oct 15, 2024, the company has ‪43.00 K‬ employees. See our rating of the largest employees — is Eli Lilly and Company on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Eli Lilly and Company EBITDA is ‪15.04 B‬ USD, and current EBITDA margin is 34.73%. See more stats in Eli Lilly and Company financial statements.
Like other stocks, LLY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Eli Lilly and Company stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Eli Lilly and Company technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Eli Lilly and Company stock shows the buy signal. See more of Eli Lilly and Company technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.